A Smart Metal-Organic Framework Nanomaterial for Lung Targeting.
Despite high morbidity and mortality associated with lung diseases, addressing drugs towards lung tissue remains a pending task. Particle lung filtration has been proposed for passive lung targeting and drug delivery. However, toxicity issues derived from the long-term presence of the particles must be overcome. By exploiting some of the ignored properties of nanosized metal-organic frameworks it is possible to achieve impressive antitumoral effects on experimental lung tumors, even without the need to engineer the surface of the material. In fact, it was discovered that, based on unique pH-responsiveness and reversible aggregation behaviors, nanoMOF was capable of targeting lung tissue. At the neutral pH of the blood, the nanoMOFs form aggregates with the adequate size to be retained in lung capillaries. Within 24 h they then disaggregate and release their drug payload. This phenomenon was compatible with lung tissue physiology.
['Simon-Yarza|Teresa|T|0000-0002-2678-0776', 'Giménez-Marqués|Mónica|M|0000-0002-4931-5711', 'Mrimi|Rhizlaine|R|', 'Mielcarek|Angelika|A|', 'Gref|Ruxandra|R|0000-0002-7869-0908', 'Horcajada|Patricia|P|0000-0002-6544-5911', 'Serre|Christian|C|0000-0003-3040-2564', 'Couvreur|Patrick|P|0000-0001-7961-5443']
D000970:Antineoplastic Agents D049109:Cell Proliferation D016503:Drug Delivery Systems D004354:Drug Screening Assays, Antitumor D006801:Humans D008175:Lung Neoplasms D000073396:Metal-Organic Frameworks D049329:Nanostructures D010316:Particle Size D013499:Surface Properties
metal-organic frameworks drug delivery nanoparticles